Gibson Dunn has advised Denali Therapeutics. Goodwin Procter and Maiwald have advised Royalty Pharma. Denali Therapeutics Inc. (Nasdaq: DNL) and Royalty Pharma plc (Nasdaq: RPRX) have...
Denali Therapeutics Enters $275 Million Synthetic Royalty Funding Agreement with Royalty Pharma
Astira Capital Partners Acquires CallRevu from Serent Capital
Gibson Dunn has advised Serent Capital and CallRevu, and Kirkland & Ellis has advised Astira Capital Partners. Serent Capital has announced the acquisition of its portfolio...
XenoTherapeutics to Acquire ESSA Pharma in All-Cash Agreement Backed by XOMA Royalty
Skadden, Arps, Slate, Meagher & Flom LLP, alongside Blake, Cassels & Graydon LLP, have advised ESSA Pharma Inc. Stikeman Elliott LLP and Gibson, Dunn & Crutcher...



























